A group from Division of Neuropsychiatry, Department of Neuroscience, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan has reported about a new glycan marker for predicting depressive disorder.
https://www.nature.com/articles/s41598-024-80507-x
It was found that plasma extracellular vesicles (EVs) containing WGA-binding von Willebrand factor (vWF) (WGA-vWF) could be a diagnostic marker for the diagnosis of patients with major depressive disorder (MDD) in a depressive state regardless of gender and age.
WGA-vWF expression was significantly lower in plasma EVs of patients with MDD in a depressive state than those of healthy control participants (HCs). ROC analysis indicated that the AUC value for the diagnosis was 0.92 (95% CI 0.82–1.00) between patients with MDD and HCs. Furthermore, WGA-vWF expression remarkably increased from depressive to remission processes. With using this result, it was possible to distinguish between patients with MDD in depressive and remission states (AUC of 0.98, 95% CI 0.93–1.00).
